Ganovo (R) Phase III Clinical Study Won the Top Award at the Infectious Disease National Congress of Chinese Medical Association

HANGZHOUand SHAOXING,China,July 30,2018 -- Ascletis announced today the Ganovo® phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association. Professor Wei Lai,the Director of the Institute ofHepatologyofPeking University,also the principal investigator of Ganovo's clinical trial,was pleased to accept this award based on a unanimous vote by a professional reviewing committee convened bytop nationalexperts. The awarded paper won the highest scientific merits out of 577 conference papers submitted this year.Ganovo regimen demonstrated excellent results of a cure rate of 97 percent(SVR12) in genotype 1 non-cirrhotic patients,within a 12-week treatment duration.

Professor Wei Lai said,"This award showcased the outstanding recognition to Ganovo from the China Medical Association (CMA) and KOL's endorsement to China-driven self-innovation encouraged bythe fast growth of the China bio-tech industry in recent years. As the first Direct-acting Anti-viral Agent (DAA) developed and launched successfully by a domestic company in China,Ganovo has shown excellent efficacy,better safety and tolerability. I sincerely hope Ganovo will make alarger impact and significant contribution to the elimination of HCV disease in China."

The National Congress of Chinese Society of the Infectious Disease is the largest and most influential academicconference in China. It attracted more than 2,000 experts and doctors who participated in the conference this year from July 26-29.The award further reinforces the medical community's confidence in Ganovo's excellent efficacy,better safety and tolerability,strong commitment to high quality drugs,and service to Chinese patients delivered by Ascletis as a local innovative biotech company.